Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Norma Choucha"'
Autor:
Sonya A MacParland, Marc Bilodeau, Jason Grebely, Julie Bruneau, Curtis Cooper, Marina Klein, Selena M Sagan, Norma Choucha, Louise Balfour, Frank Bialystok, Mel Krajden, Jennifer Raven, Eve Roberts, Rodney Russell, Michael Houghton, D Lorne Tyrrell, Jordan J Feld
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 28, Iss 9, Pp 481-487 (2014)
Hepatitis C virus (HCV) currently infects approximately 250,000 individuals in Canada and causes more years of life lost than any other infectious disease in the country. In August 2011, new therapies were approved by Health Canada that have achieved
Externí odkaz:
https://doaj.org/article/2476bb3e96734802921ca6a8e3bc7b10
Autor:
Jason Grebely, Marc Bilodeau, Jordan J Feld, Julie Bruneau, Benedikt Fischer, Jennifer F Raven, Eve Roberts, Norma Choucha, Rob P Myers, Selena M Sagan, Joyce A Wilson, Frank Bialystok, D Lorne Tyrrell, Michael Houghton, Mel Krajden, on behalf of the National CIHR Research Training Program in Hepatitis C
Publikováno v:
Canadian Journal of Gastroenterology, Vol 27, Iss 11, Pp 627-632 (2013)
In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of
Externí odkaz:
https://doaj.org/article/57253eb307e94ad1b36afc858508d059
Autor:
Jordan J. Feld, Norma Choucha, D. Lorne Tyrrell, Curtis Cooper, Louise Balfour, Jason Grebely, Selena M. Sagan, Marc Bilodeau, Marina B. Klein, Sonya A. MacParland, Mel Krajden, Frank Bialystok, Rodney S. Russell, Michael Houghton, Jennifer F Raven, Eve A. Roberts, Julie Bruneau
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 28, Iss 9, Pp 481-487 (2014)
Hepatitis C virus (HCV) currently infects approximately 250,000 individuals in Canada and causes more years of life lost than any other infectious disease in the country. In August 2011, new therapies were approved by Health Canada that have achieved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899b1bb82d72e64fa536a584aafe643f
https://doi.org/10.1155/2014/704919
https://doi.org/10.1155/2014/704919
Autor:
Jason Grebely, Marc Bilodeau, Jordan J Feld, Julie Bruneau, Benedikt Fischer, Jennifer F Raven, Eve Roberts, Norma Choucha, Rob P Myers, Selena M Sagan, Joyce A Wilson, Frank Bialystok, D Lorne Tyrrell, Michael Houghton, Mel Krajden, on behalf of the National CIHR Research Training Program in Hepatitis C
Publikováno v:
Scopus-Elsevier
Canadian Journal of Gastroenterology, Vol 27, Iss 11, Pp 627-632 (2013)
ResearcherID
Canadian Journal of Gastroenterology, Vol 27, Iss 11, Pp 627-632 (2013)
ResearcherID
In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e58e85c67428de2dd29d509c96b287
http://www.scopus.com/inward/record.url?eid=2-s2.0-84887260144&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-84887260144&partnerID=MN8TOARS
